AMPE News and Press, Ampio Pharmaceuticals Inc. From 05/22/19

ENGLEWOOD, Colo. , May 22, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced updates on subjects of interest to shareholders. Clinical:  The results of the AP-003-C open label extension study outlining the safety and efficacy of re...

Nano cap Ampio Pharmaceuticals (NYSEMKT: AMPE ) slips  5%  premarket on light volume in reaction to its announcement that the FDA does not want it to start its confirmatory trial of Ampion in patients with knee osteoarthritis without the agency's agreement of the trial design. ...

ENGLEWOOD, Colo. , April 29, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has received comments from the U.S. Food and Drug Administration (FDA) regarding their Special Protocol Assessment (SPA). The FDA recommended the Company not start t...

We believe CorMedix ( CRMD ) represents the classic case of an extremely overvalued small-cap biotech due to a large and enthusiastic retail shareholder base greatly overestimating a market opportunity. At the same time, in the next several months a critically important binary event is due - t...

ENGLEWOOD, Colo. , March 26, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that on March 11 , 2019, the Company resubmitted a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA) for a confirmatory Phase III clinical ...

ENGLEWOOD, Colo. , March 6, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today updates the regulatory status of Ampion™. Food and Drug Administration (FDA) provided guidance that Ampio should complete an additional trial of Kellgren Lawrence Grade...

ENGLEWOOD, Colo. , Feb. 6, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced it had received an initial response from the U.S. Food and Drug Administration (FDA), Office of Tissue and Advanced Therapies division regarding the Company's submission of a propo...

We at White Diamond Research like shorting medical device companies with an inefficient product or products. Last year, we exposed Transenterix ( TRXC ) and Viveve Systems ( VIVE ) as each has a medical device that is fundamentally flawed. Our next medical device stock short idea is Heli...